This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
or H2 -receptor antagonists) plus any two of amoxycillin, clarithromycin or a nitromidazole; b) only primary studies were included; c) adequate data; d) regimens were specified; e) individual primary study results presented in synthesis of two or more studies; f) no duplicated studies; g) assessment of H. pylori status at least one month after stopping eradication therapy.
Sources searched to identify primary studies
A Medline search was carried out in conjunction with a manual search of abstracts reporting the resultsof eradication therapies for the period 1992-1995, from meetings of the British Society of Gastroenterology, the American Association of Gastroenterology, the United European Gastroenterology Week, the World Congress of Gastroenterology, and the Annual International H. pylori meetings.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Three-hundred and fifty-two (352) studies were included in the analysis (from more than 1,500 publications examined). More than 50% of the studies included were RCTs.
Methods of combining primary studies
The primary study results were combined by weighting each result by its corresponding sample size.
Investigation of differences between primary studies
Differences were investigated in terms of measures of patient compliance and the study designs used (random versus nonrandom patient allocation).
Results of the review
The eradication rates, overall side effects, and serious side-effects were estimated to be as follows:
(1) omeprazole 40 mg/day + amoxycillin 2 g/day, 60%, 14%, and 2%, respectively; (2) omeprazole 40 mg/day + clarithromycin 1 mg/day, 68%, 26%, and 3%, respectively; (3) bismuth 480 mg/day + tetracycline 2 g/day + metronidazole 1.2 g/day, 78%, 40%, and 4%, respectively; (4) bismuth 480 mg/day + tetracycline 2 g/day + metronidazole 1.2 g/day + omeprazole 40 mg/day, 86%, 40%, 4%, respectively; (5) omeprazole 40 mg/day + amoxycillin 1.5 g/day + metronidazole 1.2 g/day, 85%, 39%, and 2%, respectively; (6) omeprazole 40 mg/day + amoxycillin 2 g/day + clarithromycin 0.5 g/day, 86%, 22%, and 1%, respectively; (7) omeprazole 20 mg/day + clarithromycin 0.5 g/day + tinidazole 1 g/day, more than 90%, 7%, and less than 1 %, respectively.
Measure of benefits used in the economic analysis
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The eradication rate and side-effects were the measures of benefits used in the economic analysis. The eradication rate was defined as absence of H. pylori on testing at least one month after stopping therapy.
Direct costs
The resource quantities were not reported separately from the prices. The cost analysis was restricted to drug use. The cost estimation was based on actual data derived from the information regarding the implemented protocol. The price date used in the analysis was not clearly reported.
Currency
UK Pounds Sterling ().
Sensitivity analysis
No sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
The eradication rates and serious side-effects were estimated to be as follows:
(1) omeprazole 40 mg/day + amoxycillin 2 g/day, 60% and 2%, respectively;
(2) omeprazole 40 mg/day + clarithromycin 1 mg/day, 68% and 3%, respectively; (3) bismuth 480 mg/day + tetracycline 2 g/day + metronidazole 1.2 g/day, 78% and 4%, respectively; (4) bismuth 480 mg/day + tetracycline 2 g/day + metronidazole 1.2 g/day + omeprazole 40 mg/day, 86% and 4%, respectively;
(5) omeprazole 40 mg/day + amoxycillin 1.5 g/day + metronidazole 1.2 g/day, 85% and 2%, respectively; (6) omeprazole 40 mg/day + amoxycillin 2 g/day + clarithromycin 0.5 g/day, 86% and 1%, respectively; (7) omeprazole 20 mg/day + clarithromycin 0.5 g/day + tinidazole 1 g/day, more than 90% and less than 1%, respectively.
Cost results
The costs associated with the corresponding single treatments were reported to be as follows:
(1) omeprazole 40 mg/day + amoxycillin 2 g/day, 40;
(2) omeprazole 40 mg/day + clarithromycin 1 mg/day, 80; (3) bismuth 480 mg/day + tetracycline 2 g/day + metronidazole 1.2 g/day, 15; (4) bismuth 480 mg/day + tetracycline 2 g/day + metronidazole 1.2 g/day + omeprazole 40 mg/day, 30;
(5) omeprazole 40 mg/day + amoxycillin 1.5 g/day + metronidazole 1.2 g/day, 25;
(6) omeprazole 40 mg/day + amoxycillin 2 g/day + clarithromycin 0.5 g/day, 30;
(7) omeprazole 20 mg/day + clarithromycin 0.5 g/day + tinidazole 1 g/day, 30.
